Why the study?
Early diagnosis and prognosis are important for managing cardiovascular disease, and extracellular vesicles have been related to the disease as potential novel biomarkers.
Key points are not available for this paper at this time.
Design
Review
EVs may aid CVD biomarker development; leaves open clinical translation without prospective trials.
Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality worldwide. Early diagnosis and the development of a prognosis is important for management or secondary prevention of the disease. In the past few decades, various biomarkers have been identified for improved risk assessment, more accurate diagnosis and prognosis, and a better understanding of the underlying pathophysiology in CVD. Extracellular vesicles (EVs) are thought to be important to cell-to-cell communication in the heart, and EV counts, cellular origin, and EV content have been related to CVD. This review examines current evidence for the potential application of EVs as a new class of biomarkers in CVD.
No takes yet. Share an insight, caveat, or question.
Christoph Lipps (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: